Then, we hypothesized that SGLT2 inhibitor treatment could up-regulate the expression of STING in osteosarcoma cells, which was verified by RT-PCR and Western blot analyses (Fig. 4b, c and Supplementary Fig. 3a). This evidence concerns the gene SLC5A2 and osteosarcoma.